<?xml version="1.0" encoding="UTF-8"?>
<search_results count="100">
  <query>Sovaldi AND Ribavirin</query>
<!-- Additional study fields may be added over time -->  <study rank="1">
    <nct_id>NCT02165189</nct_id>
    <title>An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitits C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Scientific Affairs, LLC</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>46</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR104281</other_id>
      <other_id>TMC435HPC2009</other_id>
    </other_ids>
    <first_received>June 10, 2014</first_received>
    <start_date>August 2014</start_date>
    <completion_date>November 2015</completion_date>
    <last_updated>October 21, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>GALAXY</acronym>
    <primary_completion_date>October 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response After 12 Weeks of end of Treatment (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response After 4 Weeks of end of Treatment (SVR4)</outcome_measure>
      <outcome_measure>Percentage of Participants With Undetectable Hepatitis C Virus Ribonucleic Acid (HCV-RNA)</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Change From Baseline in Hepatitis C Symptom and Impact Questionnaire Version 4 (HCV-SIQv4) Score at Week 24 (for Arms 1 and 2) and Week 36 (for Arm 3)</outcome_measure>
      <outcome_measure>Change From Baseline in EuroQol 5 - Dimension (EQ-5D) Questionnaire Score at Weeks 4, 8, 12, 16, 20, 24 (for all treatment arms) and Week 36 (for Arm 3)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Colorado</state>
      <state>Florida</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02165189</url>
  </study>
  <study rank="2">
    <nct_id>NCT02156570</nct_id>
    <title>DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kirby Institute</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VHCRP1206</other_id>
    </other_ids>
    <first_received>June 3, 2014</first_received>
    <start_date>October 2014</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>April 6, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>DARE-CII</acronym>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR 12</outcome_measure>
      <outcome_measure>SVR 24</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
      <country>New Zealand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02156570</url>
  </study>
  <study rank="3">
    <nct_id>NCT02464631</nct_id>
    <title>To Evaluate the Safety and Efficacy of Sofosbuvir and Ribavirin in Patients With HCV (Genotype 3) Related Decompensated Cirrhosis</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV Related Cirrhosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir + Ribavirin 1</intervention>
      <intervention type="Drug">Sofosbuvir + Ribavirin 2</intervention>
      <intervention type="Drug">Sofosbuvir + Ribavirin 3</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institute of Liver and Biliary Sciences, India</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>450</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ILBS-HCV-001</other_id>
    </other_ids>
    <first_received>May 22, 2015</first_received>
    <start_date>June 2015</start_date>
    <completion_date>June 2018</completion_date>
    <last_updated>June 26, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Primary efficacy end point is SVR 24 defined as HCV RNA &lt;LLOQ (lower limit of quantification)</outcome_measure>
      <outcome_measure>The secondary endpoint is any AE (Adverse Event) leading to permanent discontinuation of study drugs.</outcome_measure>
      <outcome_measure>Mortality at 6 months post therapy in all the 3 groups.</outcome_measure>
      <outcome_measure>Improvement in the liver function as determined by CTP (Child-Turcotte-Pugh score), MELD (Model for End Stage liver Disease)more than 2 points at 6 months and 1 year.</outcome_measure>
      <outcome_measure>Number of new cases of Hepatocellular Carcinoma at end of therapy and at 6 months post therapy in all the 3 groups.</outcome_measure>
      <outcome_measure>Reduction in HVPG &gt;20% to baseline after 1 year in all the 3 groups.</outcome_measure>
      <outcome_measure>SVR 4 defined as HCV RNA &lt;LLOQ (lower limit of quantification)</outcome_measure>
      <outcome_measure>SVR 12 defined as HCV RNA &lt;LLOQ (lower limit of quantification)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>India</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02464631</url>
  </study>
  <study rank="4">
    <nct_id>NCT01687257</nct_id>
    <title>Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Cirrhosis</condition>
      <condition>Portal Hypertension</condition>
      <condition>With or Without Liver Decompensation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0125</other_id>
      <other_id>2012-002457-29</other_id>
    </other_ids>
    <first_received>September 12, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>October 2015</completion_date>
    <last_updated>October 8, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Change in Hepatic Venous Pressure Gradient (HVPG) measurements</outcome_measure>
      <outcome_measure>Change in Child-Pugh-Turcotte (CPT) score</outcome_measure>
      <outcome_measure>Change in Model for End-Stage Liver Disease (MELD) score</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response at 4, 24, and 48 weeks after discontinuation of therapy (SVR4, SVR24, SVR48)</outcome_measure>
      <outcome_measure>Proportion of participants experiencing viral breakthrough</outcome_measure>
      <outcome_measure>Proportion of participants experiencing viral relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>France</country>
      <country>New Zealand</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Colorado</state>
      <state>Massachusetts</state>
      <state>Minnesota</state>
      <state>Pennsylvania</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01687257</url>
  </study>
  <study rank="5">
    <nct_id>NCT02292719</nct_id>
    <title>A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With and Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ombitasvir/ABT-450/r</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M14-567</other_id>
      <other_id>2014-003147-35</other_id>
    </other_ids>
    <first_received>November 13, 2014</first_received>
    <start_date>December 2014</start_date>
    <completion_date>May 2017</completion_date>
    <last_updated>October 16, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants with sustained virologic response 12 weeks (SVR12) post-treatment</outcome_measure>
      <outcome_measure>Percentage of participants with on-treatment virologic failure</outcome_measure>
      <outcome_measure>Percentage of participants with virologic relapse after treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>New Zealand</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Georgia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02292719</url>
  </study>
  <study rank="6">
    <nct_id>NCT01188772</nct_id>
    <title>Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Placebo to match sofosbuvir</intervention>
      <intervention type="Drug">PEG</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>147</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>P7977-0422</other_id>
    </other_ids>
    <first_received>August 23, 2010</first_received>
    <start_date>August 2010</start_date>
    <completion_date>May 2012</completion_date>
    <last_updated>April 2, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>January 6, 2014</firstreceived_results_date>
    <primary_completion_date>April 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Who Experienced Adverse Events During the Sofosbuvir Treatment Period</outcome_measure>
      <outcome_measure>Change in HCV RNA From Baseline to Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Virologic Response at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Complete Early Virologic Response at Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants With Extended Rapid Virologic Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Response at the End of Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Post-treatment Week 12 (SVR12) and 24 (SVR24)</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007 (Cmax at Day 8)</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007 (Cmax at Day 15)</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007 (Cmax at Day 29)</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007 (AUCtau at Day 8)</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007 (AUCtau at Day 15)</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007 (AUCtau at Day 29)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Developed Resistance to Sofosbuvir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Texas</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01188772</url>
  </study>
  <study rank="7">
    <nct_id>NCT02168361</nct_id>
    <title>The SIM-SOF Trial for Hepatitis C</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon alfa-2b</intervention>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Center For Hepatitis C, Atlanta, GA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>82</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CHC-21</other_id>
    </other_ids>
    <first_received>June 17, 2014</first_received>
    <start_date>December 2013</start_date>
    <completion_date>November 2014</completion_date>
    <last_updated>June 19, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response 12 (SVR-12)</outcome_measure>
      <outcome_measure>Virologic Relapse</outcome_measure>
      <outcome_measure>Virologic Breakthrough</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Georgia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02168361</url>
  </study>
  <study rank="8">
    <nct_id>NCT02596880</nct_id>
    <title>Sofosbuvir, Daclatasvir, Ribavirin for HCV Cirrhotics</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Cirrhosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tehran University of Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>94-02-159-30278</other_id>
    </other_ids>
    <first_received>November 3, 2015</first_received>
    <start_date>September 2015</start_date>
    <completion_date>May 2016</completion_date>
    <last_updated>November 9, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>SD100</acronym>
    <primary_completion_date>March 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The sustained viral response rate</outcome_measure>
      <outcome_measure>Adverse drug events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Iran, Islamic Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02596880</url>
  </study>
  <study rank="9">
    <nct_id>NCT02021643</nct_id>
    <title>Efficacy and Safety of Sofosbuvir Plus Ribavirin in Subjects With Chronic HCV Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">PegIFNα</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>657</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0115</other_id>
    </other_ids>
    <first_received>November 26, 2013</first_received>
    <start_date>December 2013</start_date>
    <completion_date>October 2016</completion_date>
    <last_updated>November 30, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Proportion of participants permanently discontinuing study drug(s) due to an adverse event (AE)</outcome_measure>
      <outcome_measure>Proportion of participants with: HCV RNA &lt; LLOQ at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants experiencing viral breakthrough</outcome_measure>
      <outcome_measure>Proportion of participants experiencing viral relapse</outcome_measure>
      <outcome_measure>Change from baseline in HCV RNA (log10 IU/mL)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
      <country>Hong Kong</country>
      <country>Korea, Republic of</country>
      <country>Taiwan</country>
      <country>Vietnam</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02021643</url>
  </study>
  <study rank="10">
    <nct_id>NCT02405013</nct_id>
    <title>Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir and Ribavirin for the Treatment of Genotype 1, 2 and 4 Hepatitis C Virus-infected Patients in West and Central Africa</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRS 12311 TAC</other_id>
    </other_ids>
    <first_received>February 20, 2015</first_received>
    <start_date>November 2015</start_date>
    <completion_date>November 2016</completion_date>
    <last_updated>December 2, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>TAC</acronym>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Viral Load Response (SVR)</outcome_measure>
      <outcome_measure>Tolerance</outcome_measure>
      <outcome_measure>Viral kinetics as measured by SVR 24 and HCV-RNA</outcome_measure>
      <outcome_measure>HIV treatment clinical parameters</outcome_measure>
      <outcome_measure>Liver fibrosis</outcome_measure>
      <outcome_measure>Adherence measured by number of remaining tablets at each visit based on the number of tablets should have been taken as a percentage of the total dose</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
      <outcome_measure>Performance of an unit of nanotechnology</outcome_measure>
      <outcome_measure>Setting up the network:</outcome_measure>
      <outcome_measure>Integration Access initiatives evaluated by the number of patients off protocol that will have access to new anti-HCV treatment due to &quot;ACCESS&quot; programs of pharmaceutical companies conducting such programs in Sub-Saharan Africa</outcome_measure>
      <outcome_measure>Biological events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Cameroon</country>
      <country>Côte D'Ivoire</country>
      <country>Senegal</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02405013</url>
  </study>
  <study rank="11">
    <nct_id>NCT02551861</nct_id>
    <title>A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-377</other_id>
      <other_id>2015-003468-36</other_id>
    </other_ids>
    <first_received>September 15, 2015</first_received>
    <start_date>December 2015</start_date>
    <completion_date>June 2017</completion_date>
    <last_updated>November 18, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects with sustained virologic response (SVR12) treated with Daclatasvir + Sofosbuvir (DCV+SOF)</outcome_measure>
      <outcome_measure>Safety measured by number of incidence of deaths, serious adverse events (SAE)s, discontinuation due to adverse events (AE)s, Grade 3/4 AEs and Grade 3/4 laboratory abnormalities observed from clinical laboratory testing</outcome_measure>
      <outcome_measure>Antiviral activity measured by the proportion of subjects who achieve HCV RNA &lt; lower limit of quantification (LLOQ) - at during and after treatment in each treatment arm</outcome_measure>
      <outcome_measure>Proportion of subjects with CC, CT or TT IL28B genotype who achieve SVR12 in each treatment arm</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02551861</url>
  </study>
  <study rank="12">
    <nct_id>NCT01910636</nct_id>
    <title>Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>153</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0118</other_id>
    </other_ids>
    <first_received>July 23, 2013</first_received>
    <start_date>February 2013</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>March 13, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>March 13, 2015</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01910636</url>
  </study>
  <study rank="13">
    <nct_id>NCT02483156</nct_id>
    <title>Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Tablet Plus Ribavirin Tablet (Part A) Versus Single Tablet of EHCV Containing Sofosbuvir, Ribavirin, and Natural Anti-hemolytic (B) in Egyptian Adults With Chronic Genotype 4 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis c</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">single tablet of EHCV containing Sofosbuvir, Ribavirin, and Natural anti-hemolytic</intervention>
      <intervention type="Drug">Sofosbuvir tablet (SOF)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Egyptian Liver Hospital</lead_sponsor>
      <collaborator>Wadi El Nil Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ELH - 2015</other_id>
    </other_ids>
    <first_received>June 19, 2015</first_received>
    <start_date>July 2015</start_date>
    <last_updated>September 15, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Who Experienced Adverse Events During Treatment Period</outcome_measure>
      <outcome_measure>Change in Circulating HCV RNA</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02483156</url>
  </study>
  <study rank="14">
    <nct_id>NCT01435044</nct_id>
    <title>Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">GS-0938</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">Placebo to match sofosbuvir</intervention>
      <intervention type="Drug">Placebo to match GS-0938</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
      <collaborator>Quintiles</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>239</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>P2938-0721</other_id>
    </other_ids>
    <first_received>September 9, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>May 2013</completion_date>
    <last_updated>January 7, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>QUANTUM</acronym>
    <primary_completion_date>April 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants with sustained virologic response (SVR) 12 weeks after discontinuation of study drug (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Experienced Adverse Events</outcome_measure>
      <outcome_measure>Change from baseline in HCV RNA</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ during treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With ALT Normalization</outcome_measure>
      <outcome_measure>Percentage of participants with SVR at 4 and 24 weeks after discontinuation of study drug (SVR4; SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Developed Resistance to Sofosbuvir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01435044</url>
  </study>
  <study rank="15">
    <nct_id>NCT01641640</nct_id>
    <title>Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">PEG</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>328</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0110</other_id>
    </other_ids>
    <first_received>July 9, 2012</first_received>
    <start_date>June 2012</start_date>
    <completion_date>April 2013</completion_date>
    <last_updated>April 8, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>February 25, 2014</firstreceived_results_date>
    <acronym>NEUTRINO</acronym>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response (SVR)12</outcome_measure>
      <outcome_measure>Number of Participants Experiencing Adverse Events Leading to Permanent Discontinuation of Study Drug</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR4</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR24</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Indiana</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01641640</url>
  </study>
  <study rank="16">
    <nct_id>NCT02455167</nct_id>
    <title>Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprivir (SMV)</intervention>
      <intervention type="Drug">Sofosbuvir (SOF)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Colorado, Denver</lead_sponsor>
      <collaborator>Janssen Scientific Affairs, LLC</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>14-0919</other_id>
      <other_id>UL1TR001082</other_id>
    </other_ids>
    <first_received>April 21, 2015</first_received>
    <start_date>May 2015</start_date>
    <completion_date>August 2016</completion_date>
    <last_updated>October 2, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The sustained virologic response (SVR) in patients infected with HCV genotype 1, cirrhosis, and early clinical decompensation</outcome_measure>
      <outcome_measure>Hepatic improvement during and after Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) treatment using a new test of liver function, HepQuant-SHUNT.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Colorado</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02455167</url>
  </study>
  <study rank="17">
    <nct_id>NCT02319031</nct_id>
    <title>Safety and Efficacy Study of Daclatasvir 60mg, Sofosbuvir 400mg, and Ribavirin (Dosed Based Upon Weight) in Subjects With Chronic Genotype 3 Hepatitis C Infection With or Without Prior Treatment Experience and Compensated Advanced Cirrhosis for 12 or 16 Weeks</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-326</other_id>
    </other_ids>
    <first_received>December 12, 2014</first_received>
    <start_date>February 2015</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>December 8, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects with sustained virologic response a follow up Weeks 12 (SVR12), defined as HCV RNA &lt; lower limit of quantification (LLOQ) target detected (TD) or target not detected (TND)</outcome_measure>
      <outcome_measure>On treatment safety, as measured by frequency of Serious Adverse Event (SAE)s, discontinuation due to Adverse Event (AE)s, Grade 3/4 AEs, and Grade 3/4 laboratory abnormalities</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve HCV RNA &lt; LLOQ-TD/TND</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02319031</url>
  </study>
  <study rank="18">
    <nct_id>NCT01559844</nct_id>
    <title>Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Hepatocellular Carcinoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>61</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P7977-2025</other_id>
    </other_ids>
    <first_received>March 5, 2012</first_received>
    <start_date>March 2012</start_date>
    <completion_date>October 2014</completion_date>
    <last_updated>June 2, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>May 12, 2015</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Posttransplant Virologic Response (pTVR) at Posttransplant Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Any Adverse Event Leading to Permanent Discontinuation of Sobosbuvir Prior to Receiving Transplant</outcome_measure>
      <outcome_measure>Percentage of Participants With Graft Loss Following Transplant</outcome_measure>
      <outcome_measure>Number of Participants Who Died</outcome_measure>
      <outcome_measure>Percentage of Participants With Posttransplant Virologic Response (pTVR) Through Posttransplant Week 48</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ (ie, 25 mL/IU) During Treatment Through Week 48</outcome_measure>
      <outcome_measure>HCV RNA and Change From Baseline in HCV RNA Through Week 8</outcome_measure>
      <outcome_measure>Proportion of Participants With Virologic Failure Prior to Transplant</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>New Zealand</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01559844</url>
  </study>
  <study rank="19">
    <nct_id>NCT01054729</nct_id>
    <title>Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">PEG</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>64</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>P7977-0221</other_id>
    </other_ids>
    <first_received>January 21, 2010</first_received>
    <start_date>January 2010</start_date>
    <completion_date>August 2011</completion_date>
    <last_updated>March 31, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>January 6, 2014</firstreceived_results_date>
    <primary_completion_date>April 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Who Experienced Adverse Events During the Sofosbuvir Treatment Period</outcome_measure>
      <outcome_measure>Change in Circulating HCV RNA at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Virologic Response at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) at 12 and 24 Weeks After Last Dose of PEG+RBV Following Completion of 48 Weeks of Treatment</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of Sofosbuvir: Cmax at Day 0</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of Sofosbuvir: Cmax at Day 27</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of Sofosbuvir: AUCinf at Day 0</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of Sofosbuvir: AUCtau at Day 27</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007: Cmax at Day 0</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007: Cmax at Day 27</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007: AUCinf at Day 0</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007: AUCtau at Day 27</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-566500: Cmax at Day 0</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-566500: Cmax at Day 27</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-566500: AUCinf at Day 0</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-566500: AUCtau at Day 27</outcome_measure>
      <outcome_measure>Percentage of Participants Who Developed Resistance to Sofosbuvir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01054729</url>
  </study>
  <study rank="20">
    <nct_id>NCT01779518</nct_id>
    <title>Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C</title>
    <recruitment open="N">Approved for marketing</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Post-transplant Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated Interferon</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Expanded Access</study_types>
    <study_designs/>
    <other_ids>
      <other_id>GS-US-334-0139</other_id>
    </other_ids>
    <first_received>January 23, 2013</first_received>
    <last_updated>January 15, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01779518</url>
  </study>
  <study rank="21">
    <nct_id>NCT02537379</nct_id>
    <title>Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">COPE</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
      <collaborator>Chugai Pharmaceutical</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Ecologic or Community</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-1444 / COPE1501</other_id>
    </other_ids>
    <first_received>August 28, 2015</first_received>
    <start_date>September 2015</start_date>
    <completion_date>May 2018</completion_date>
    <last_updated>December 2, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Incidence of adverse drug reaction (ADR) under real world settings</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR) 12 and 24 weeks after discontinuation of therapy (SVR12 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with HCV NS5B resistance associated variants among patients who do not achieve SVR at 12 weeks</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02537379</url>
  </study>
  <study rank="22">
    <nct_id>NCT02562742</nct_id>
    <title>Use-Results Surveillance Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">REB</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Ecologic or Community</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-1879</other_id>
    </other_ids>
    <first_received>September 28, 2015</first_received>
    <start_date>November 2015</start_date>
    <completion_date>June 2018</completion_date>
    <last_updated>December 3, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Incidence of adverse drug reaction (ADR) under real world settings</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR) 12 and 24 weeks after discontinuation of therapy (SVR12 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with HCV NS5B resistance associated variants among patients who do not achieve SVR at 12 weeks</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02562742</url>
  </study>
  <study rank="23">
    <nct_id>NCT02601573</nct_id>
    <title>Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic HCV GT3 Infection</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Grazoprevir</intervention>
      <intervention type="Drug">Elbasvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>125</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>5172-083</other_id>
      <other_id>2015-003187-37</other_id>
    </other_ids>
    <first_received>November 9, 2015</first_received>
    <start_date>December 2015</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>November 9, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants achieving SVR12 (Sustained Virologic Response 12 weeks after the end of all study therapy)</outcome_measure>
      <outcome_measure>Number of participants experiencing an adverse event (AE)</outcome_measure>
      <outcome_measure>Number of participants discontinuing from study therapy due to an AE</outcome_measure>
      <outcome_measure>Percentage of participants achieving SVR24 (Sustained Virologic Response 24 weeks after the end of all study therapy)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02601573</url>
  </study>
  <study rank="24">
    <nct_id>NCT01838590</nct_id>
    <title>Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>103</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0138</other_id>
    </other_ids>
    <first_received>April 15, 2013</first_received>
    <start_date>March 2013</start_date>
    <completion_date>August 2014</completion_date>
    <last_updated>May 7, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>May 5, 2015</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing On-treatment Virologic Failure</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Virologic Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01838590</url>
  </study>
  <study rank="25">
    <nct_id>NCT02074514</nct_id>
    <title>Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>117</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0116</other_id>
    </other_ids>
    <first_received>February 26, 2014</first_received>
    <start_date>March 2014</start_date>
    <completion_date>November 2015</completion_date>
    <last_updated>December 7, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of adverse events leading to permanent discontinuation of study drug</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR) at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure and viral relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>India</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02074514</url>
  </study>
  <study rank="26">
    <nct_id>NCT01329978</nct_id>
    <title>Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">PEG</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>332</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P7977-0724</other_id>
    </other_ids>
    <first_received>March 30, 2011</first_received>
    <start_date>March 2011</start_date>
    <completion_date>August 2012</completion_date>
    <last_updated>April 24, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>January 6, 2014</firstreceived_results_date>
    <acronym>ATOMIC</acronym>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 24 Weeks Following Completion of Treatment (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Experienced Adverse Events</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks Following Completion of Treatment (SVR12)</outcome_measure>
      <outcome_measure>Change in HCV RNA at Week 2</outcome_measure>
      <outcome_measure>Change in HCV RNA at Week 4</outcome_measure>
      <outcome_measure>Change in HCV RNA at Week 8</outcome_measure>
      <outcome_measure>Change in HCV RNA at Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LOD at Week 2</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA Below &lt; LOD at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA Below &lt; LOD at Week 8</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA Below &lt; LOD at Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA Below &lt; LOD at Week 24</outcome_measure>
      <outcome_measure>Percentage of Participants With ALT Normalization at Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants With ALT Normalization at Week 24</outcome_measure>
      <outcome_measure>Percentage of Participants With ALT Normalization at Post-treatment Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Failure During Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Failure Following Treatment (Viral Relapse).</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arkansas</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>South Carolina</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01329978</url>
  </study>
  <study rank="27">
    <nct_id>NCT02371408</nct_id>
    <title>A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ravidasvir hydrochloride</intervention>
      <intervention type="Drug">sofosbuvir</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pharco Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>PPI-668-202</other_id>
    </other_ids>
    <first_received>February 1, 2015</first_received>
    <start_date>January 2015</start_date>
    <completion_date>May 2016</completion_date>
    <last_updated>October 22, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportions of patients who achieve Sustained Virologic Response at 12 weeks post-treatment (SVR12)</outcome_measure>
      <outcome_measure>Proportions of patients who achieve Sustained Virologic Response at 4 weeks post-treatment (SVR4)</outcome_measure>
      <outcome_measure>Proportions of patients who achieve Sustained Virologic Response at 24 weeks post-treatment (SVR 24)</outcome_measure>
      <outcome_measure>Proportion of treated study participants prematurely discontinuing study treatment for any reason, proportion prematurely discontinuing treatment for lack of efficacy or for clinical adverse events or laboratory abnormalities</outcome_measure>
      <outcome_measure>Proportion of patients experiencing treatment-emergent adverse events, and proportion of patients experiencing adverse events considered to be probably or possibly related to one or more of the study drugs</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02371408</url>
  </study>
  <study rank="28">
    <nct_id>NCT01687270</nct_id>
    <title>Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Recurrent Chronic Hepatitis C Virus</condition>
      <condition>Post Liver Transplant</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0126</other_id>
      <other_id>2012-002417-19</other_id>
    </other_ids>
    <first_received>September 12, 2012</first_received>
    <start_date>November 2012</start_date>
    <completion_date>August 2014</completion_date>
    <last_updated>December 11, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>December 11, 2014</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Discontinue Study Drug Due to an Adverse Event</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) at 4, 24, and 48 Weeks After Discontinuation of Therapy (SVR4, SVR24, and SVR48)</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ at Weeks 12 and 24</outcome_measure>
      <outcome_measure>HCV RNA and Change From Baseline at Weeks 2, 4, and 8</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>France</country>
      <country>Germany</country>
      <country>New Zealand</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Indiana</state>
      <state>Kansas</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>New York</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01687270</url>
  </study>
  <study rank="29">
    <nct_id>NCT02128542</nct_id>
    <title>Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>66</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-1379</other_id>
    </other_ids>
    <first_received>April 29, 2014</first_received>
    <start_date>June 2014</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>July 1, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>VALOR-HCV</acronym>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR) at 4 weeks after discontinuation of therapy (SVR4)</outcome_measure>
      <outcome_measure>Proportion of participants experiencing viral breakthrough</outcome_measure>
      <outcome_measure>Proportion of participants experiencing viral relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Maryland</state>
      <state>Missouri</state>
      <state>North Carolina</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02128542</url>
  </study>
  <study rank="30">
    <nct_id>NCT01962441</nct_id>
    <title>Sofosbuvir+RBV for 16 or 24 Weeks and Sofosbuvir+PEG+RBV for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">PEG</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>601</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0153</other_id>
    </other_ids>
    <first_received>October 10, 2013</first_received>
    <start_date>September 2013</start_date>
    <completion_date>June 2016</completion_date>
    <last_updated>October 27, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants achieving sustained viral response 12 weeks after discontinuation of treatment (SVR12)</outcome_measure>
      <outcome_measure>Adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with HCV RNA &lt; LLOQ during treatment</outcome_measure>
      <outcome_measure>Change from baseline in HCV RNA (log10 IU/mL)</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR) at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants experiencing viral breakthrough</outcome_measure>
      <outcome_measure>Proportion of participants experiencing viral relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>New Zealand</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Louisiana</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01962441</url>
  </study>
  <study rank="31">
    <nct_id>NCT01497366</nct_id>
    <title>Phase 3 Study of Sofosbuvir and Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">PEG</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>527</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P7977-1231</other_id>
    </other_ids>
    <first_received>December 19, 2011</first_received>
    <start_date>December 2011</start_date>
    <completion_date>April 2013</completion_date>
    <last_updated>March 4, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>January 15, 2014</firstreceived_results_date>
    <acronym>FISSION</acronym>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After Stopping All Study Drugs (SVR12)</outcome_measure>
      <outcome_measure>Number of Participants Who Experienced Adverse Events (AEs) and Graded Laboratory Abnormalities</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 24 Weeks After Stopping All Study Drugs (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ on Treatment</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Failure During Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse Following Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Italy</country>
      <country>Netherlands</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
      <country>Sweden</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Mississippi</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01497366</url>
  </study>
  <study rank="32">
    <nct_id>NCT01808248</nct_id>
    <title>Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">PEG</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>47</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0151</other_id>
    </other_ids>
    <first_received>March 1, 2013</first_received>
    <start_date>February 2013</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>September 5, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>September 5, 2014</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing On-treatment Virologic Failure</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01808248</url>
  </study>
  <study rank="33">
    <nct_id>NCT02304159</nct_id>
    <title>Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Cirrhosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">daclatasvir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tarek I. Hassanein, M.D., FACP, FAG, AGAF</lead_sponsor>
      <collaborator>Southern California Research Center</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444284</other_id>
    </other_ids>
    <first_received>November 17, 2014</first_received>
    <start_date>January 2015</start_date>
    <completion_date>November 2017</completion_date>
    <last_updated>November 21, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants with adverse events</outcome_measure>
      <outcome_measure>Number of participants with abnormal safety laboratory tests (ALT and/or Total Bilirubin) that required discontinuing study drugs</outcome_measure>
      <outcome_measure>Number of participants with undetectable HCV virus 12 weeks after stopping study drugs</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02304159</url>
  </study>
  <study rank="34">
    <nct_id>NCT02541409</nct_id>
    <title>Directly Observed Therapy for HCV in Chennai, India</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Pegylated Interferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Johns Hopkins Bloomberg School of Public Health</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
      <collaborator>YR Gaitonde Centre for AIDS Research and Education</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>R01DA02672</other_id>
      <other_id>R01DA026727</other_id>
    </other_ids>
    <first_received>August 31, 2015</first_received>
    <start_date>September 2015</start_date>
    <completion_date>September 2016</completion_date>
    <last_updated>September 1, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>C-DOT</acronym>
    <primary_completion_date>September 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects that complete their course of treatment</outcome_measure>
      <outcome_measure>Sustained virologic response 12 weeks after treatment is completed (SVR12) as assessed by undetectable HCV RNA measured 12 weeks after treatment completion</outcome_measure>
      <outcome_measure>Number of participants with treatment-related serious adverse events by laboratory tests and physician examination</outcome_measure>
      <outcome_measure>Change in insulin resistance as assessed by homeostasis model assessment - insulin resistance (HOMA-IR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>India</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02541409</url>
  </study>
  <study rank="35">
    <nct_id>NCT02220868</nct_id>
    <title>Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
      <condition>HIV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir, Ribavirin, and Stribild</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Saint Michael's Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>IN-US-334-1527</other_id>
    </other_ids>
    <first_received>August 18, 2014</first_received>
    <start_date>July 2014</start_date>
    <completion_date>August 2015</completion_date>
    <last_updated>August 19, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>• SVR,12 defined as undetectable HCV RNA levels for 12 weeks after the completion of therapy</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New Jersey</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02220868</url>
  </study>
  <study rank="36">
    <nct_id>NCT01984294</nct_id>
    <title>Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">GS-9669</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>101</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-0133</other_id>
    </other_ids>
    <first_received>November 8, 2013</first_received>
    <start_date>October 2013</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>April 30, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>April 30, 2015</firstreceived_results_date>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants Permanently Discontinuing Any Study Drug Due to an Adverse Event</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at 2, 4, 8, and 24 Weeks After Discontinuation of Therapy (SVR2, SVR4, SVR8, and SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing On-treatment Virologic Failure</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01984294</url>
  </study>
  <study rank="37">
    <nct_id>NCT02032875</nct_id>
    <title>Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>116</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-215</other_id>
    </other_ids>
    <first_received>January 9, 2014</first_received>
    <start_date>March 2014</start_date>
    <completion_date>January 2016</completion_date>
    <last_updated>October 20, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>August 18, 2015</firstreceived_results_date>
    <acronym>ALLY 1</acronym>
    <primary_completion_date>November 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Genotype-1 Infected Cirrhotic Participants With Sustained Virologic Response at Post-treatment Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Genotype-1 Infected Post-liver Transplanted Participants With Sustained Virologic Response at Post-treatment Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieved Sustained Virologic Response at Post-treatment Week 12 (SVR12) for All Genotypes and Genotypes 2, 3, 4, 6</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieve Hepatitis C Virus RNA Levels to be &lt; Lower Limit of Quantitation Target Detected or Target Not Detected at Each of the Following Weeks: 1, 2, 4, 6, 8, 12, End of Treatment; Follow Up Weeks 4, 8 and 12</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieve Hepatitis C Virus RNA Levels to be &lt; Lower Limit of Quantitation Target Not Detected at Each of the Following Weeks: 1, 2, 4, 6, 8, 12, End of Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With CC or Non-CC Genotype Who Achieved Sustained Virologic Response at 12 Weeks After the Last Dose of Study Drug (SVR12)</outcome_measure>
      <outcome_measure>Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), AEs Leading to Interruption, Treatment-related AEs/SAEs, Grade 3 to 4 AEs/SAEs, and Who Died During Treatment Period</outcome_measure>
      <outcome_measure>Number of Participants With Treatment Emergent Grade 3-4 Laboratory Abnormalities</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Florida</state>
      <state>Michigan</state>
      <state>Texas</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02032875</url>
  </study>
  <study rank="38">
    <nct_id>NCT01713283</nct_id>
    <title>Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0114</other_id>
    </other_ids>
    <first_received>October 17, 2012</first_received>
    <start_date>October 2012</start_date>
    <completion_date>February 2014</completion_date>
    <last_updated>November 18, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>November 18, 2014</firstreceived_results_date>
    <primary_completion_date>November 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing On-treatment Virologic Failure</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01713283</url>
  </study>
  <study rank="39">
    <nct_id>NCT02487030</nct_id>
    <title>Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-1643</other_id>
    </other_ids>
    <first_received>June 27, 2015</first_received>
    <start_date>September 2015</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>October 6, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of any adverse event leading to permanent discontinuation of study drug</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02487030</url>
  </study>
  <study rank="40">
    <nct_id>NCT02120300</nct_id>
    <title>Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>122</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-1274</other_id>
    </other_ids>
    <first_received>April 18, 2014</first_received>
    <start_date>April 2014</start_date>
    <completion_date>August 2015</completion_date>
    <last_updated>August 25, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR) at 4 weeks after discontinuation of therapy (SVR4)</outcome_measure>
      <outcome_measure>Proportion of participants with HCV RNA &lt; LLOQ on treatment</outcome_measure>
      <outcome_measure>HCV RNA change from baseline</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
      <outcome_measure>For HIV-1/HCV co-infected participants, the proportion of participants that maintain HIV-1 RNA &lt; 50 copies/mL while on HCV treatment</outcome_measure>
      <outcome_measure>For HIV-1/HCV co-infected participants, change from baseline of serum creatinine at the end of treatment</outcome_measure>
      <outcome_measure>For HIV-1/HCV co-infected participants, change from baseline of serum creatinine at posttreatment Week 12</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>District of Columbia</state>
      <state>Georgia</state>
      <state>Massachusetts</state>
      <state>Minnesota</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02120300</url>
  </study>
  <study rank="41">
    <nct_id>NCT02413593</nct_id>
    <title>Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>111</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-1701</other_id>
    </other_ids>
    <first_received>April 7, 2015</first_received>
    <start_date>April 2015</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>September 28, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of any adverse events leading to permanent discontinuation of study drug</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response 4 weeks after discontinuation of therapy (SVR4)</outcome_measure>
      <outcome_measure>Proportion of participants with HCV RNA &lt; LLOQ on treatment</outcome_measure>
      <outcome_measure>HCV RNA change from Day 1</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02413593</url>
  </study>
  <study rank="42">
    <nct_id>NCT01896193</nct_id>
    <title>Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>127</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0119</other_id>
    </other_ids>
    <first_received>July 2, 2013</first_received>
    <start_date>June 2013</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>May 7, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>April 7, 2015</firstreceived_results_date>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing On-treatment Virologic Failure</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Virologic Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Russian Federation</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01896193</url>
  </study>
  <study rank="43">
    <nct_id>NCT01768286</nct_id>
    <title>Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>441</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-0109</other_id>
    </other_ids>
    <first_received>January 10, 2013</first_received>
    <start_date>January 2013</start_date>
    <completion_date>February 2014</completion_date>
    <last_updated>November 21, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>November 21, 2014</firstreceived_results_date>
    <acronym>ION-2</acronym>
    <primary_completion_date>November 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of Adverse Events Leading to Permanent Discontinuation From Any Study Drug</outcome_measure>
      <outcome_measure>Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 1</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 2</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 8</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 24</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 1</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 2</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 4</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 8</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01768286</url>
  </study>
  <study rank="44">
    <nct_id>NCT01604850</nct_id>
    <title>Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">Placebo to match SOF</intervention>
      <intervention type="Drug">Placebo to match RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>202</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0108</other_id>
    </other_ids>
    <first_received>May 21, 2012</first_received>
    <start_date>June 2012</start_date>
    <completion_date>May 2013</completion_date>
    <last_updated>May 9, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>March 31, 2014</firstreceived_results_date>
    <acronym>FUSION</acronym>
    <primary_completion_date>February 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving SVR12</outcome_measure>
      <outcome_measure>Adverse Events Leading to Permanent Discontinuation of Study Drug</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR4</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR24</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Indiana</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01604850</url>
  </study>
  <study rank="45">
    <nct_id>NCT01783678</nct_id>
    <title>A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Human Immunodeficiency Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>275</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0124</other_id>
    </other_ids>
    <first_received>January 31, 2013</first_received>
    <start_date>January 2013</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>April 15, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>April 15, 2015</firstreceived_results_date>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>HCV RNA Change From Baseline at Week 1</outcome_measure>
      <outcome_measure>HCV RNA Change From Baseline at Week 2</outcome_measure>
      <outcome_measure>HCV RNA Change From Baseline at Week 4</outcome_measure>
      <outcome_measure>HCV RNA Change From Baseline at Week 6</outcome_measure>
      <outcome_measure>HCV RNA Change From Baseline at Week 8</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Virologic Failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01783678</url>
  </study>
  <study rank="46">
    <nct_id>NCT01542788</nct_id>
    <title>Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">Placebo to match SOF</intervention>
      <intervention type="Drug">Placebo to match RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>278</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0107</other_id>
    </other_ids>
    <first_received>February 17, 2012</first_received>
    <start_date>March 2012</start_date>
    <completion_date>February 2013</completion_date>
    <last_updated>May 8, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>January 6, 2014</firstreceived_results_date>
    <acronym>POSITRON</acronym>
    <primary_completion_date>November 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving SVR12</outcome_measure>
      <outcome_measure>Number of Participants Experiencing Adverse Events Leading to Permanent Discontinuation of Study Drug</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR4</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR24</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Indiana</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01542788</url>
  </study>
  <study rank="47">
    <nct_id>NCT02356562</nct_id>
    <title>A Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Ombitasvir/ABT-450/Ritonavir and Dasabuvir With Sofosbuvir in DAA Treatment-experienced Adults With Chronic Hepatitis C Virus Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ombitasvir/ABT-450/r</intervention>
      <intervention type="Drug">Dasabuvir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M14-224</other_id>
    </other_ids>
    <first_received>February 2, 2015</first_received>
    <start_date>February 2015</start_date>
    <completion_date>August 2016</completion_date>
    <last_updated>October 10, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of subjects with sustained virologic response 12 weeks post-treatment</outcome_measure>
      <outcome_measure>Percentage of subjects with virologic failure during treatment</outcome_measure>
      <outcome_measure>Percentage of subjects with virologic relapse after treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>North Carolina</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02356562</url>
  </study>
  <study rank="48">
    <nct_id>NCT02097966</nct_id>
    <title>EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C</title>
    <recruitment open="Y">Available</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Expanded Access</study_types>
    <study_designs/>
    <other_ids>
      <other_id>AI444-237</other_id>
    </other_ids>
    <first_received>March 25, 2014</first_received>
    <last_updated>November 19, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>Austria</country>
      <country>Germany</country>
      <country>Netherlands</country>
      <country>Sweden</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02097966</url>
  </study>
  <study rank="49">
    <nct_id>NCT02399345</nct_id>
    <title>Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus (HCV Infection Genotype 1)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ombitasvir/paritaprevir/ritonavir</intervention>
      <intervention type="Drug">dasabuvir</intervention>
      <intervention type="Drug">sofosbuvir (SOF)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M15-310</other_id>
      <other_id>2014-005280-32</other_id>
    </other_ids>
    <first_received>March 23, 2015</first_received>
    <start_date>March 2015</start_date>
    <completion_date>November 2015</completion_date>
    <last_updated>November 18, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of subjects achieving a 12-week sustained virologic response</outcome_measure>
      <outcome_measure>Percentage of subjects with on-treatment virologic failure</outcome_measure>
      <outcome_measure>Percentage of subjects with post-treatment relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
      <country>Australia</country>
      <country>New Zealand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02399345</url>
  </study>
  <study rank="50">
    <nct_id>NCT02358044</nct_id>
    <title>Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Biological">PegIntron</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Grazoprevir/Elbasvir (100 mg/50 mg) FDC</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>257</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>5172-077</other_id>
      <other_id>2014-003836-38</other_id>
    </other_ids>
    <first_received>February 3, 2015</first_received>
    <start_date>February 2015</start_date>
    <completion_date>March 2016</completion_date>
    <last_updated>October 12, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants achieving SVR12</outcome_measure>
      <outcome_measure>Number of participants experiencing at least 1 adverse event (AE) on study</outcome_measure>
      <outcome_measure>Number of participants discontinuing study therapy due to an AE</outcome_measure>
      <outcome_measure>Percentage of participants achieving sustained virologic response 24 weeks after ending study treatment (SVR24)</outcome_measure>
      <outcome_measure>Percentage of participants achieving sustained virologic response 4 weeks after ending study treatment (SVR4)</outcome_measure>
      <outcome_measure>Percentage of participants experiencing a Tier 1 safety event (parameter/AE of special interest identified a priori in protocol subject to inferential testing for statistical significance)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02358044</url>
  </study>
  <study rank="51">
    <nct_id>NCT01851330</nct_id>
    <title>Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>647</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-0108</other_id>
    </other_ids>
    <first_received>May 3, 2013</first_received>
    <start_date>May 2013</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>December 18, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>December 18, 2014</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of Adverse Events Leading to Permanent Discontinuation From Any Study Drug</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 2</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 8</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 2</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 4</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 8</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Virologic Failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01851330</url>
  </study>
  <study rank="52">
    <nct_id>NCT02175758</nct_id>
    <title>Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF (oral tablets)</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">SOF (oral granules)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-1112</other_id>
      <other_id>2014-002283-32</other_id>
    </other_ids>
    <first_received>June 24, 2014</first_received>
    <start_date>July 2014</start_date>
    <completion_date>April 2018</completion_date>
    <last_updated>November 10, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>PK Lead-in Phase: PK parameters of GS-331007 as measured by AUCtau for determining the appropriate SOF dose</outcome_measure>
      <outcome_measure>Treatment Phase: proportion of participants achieving SVR12</outcome_measure>
      <outcome_measure>Treatment Phase: incidence of any adverse event leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>PK Lead-in Phase: change from baseline in HCV RNA</outcome_measure>
      <outcome_measure>PK Lead-in Phase: incidence of adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Treatment Phase: proportion of participants achieving SVR4</outcome_measure>
      <outcome_measure>Treatment Phase: proportion of participants achieving SVR24</outcome_measure>
      <outcome_measure>Treatment Phase: proportion of participants with virologic breakthrough</outcome_measure>
      <outcome_measure>Treatment Phase: proportion of participants with virologic relapse</outcome_measure>
      <outcome_measure>Palatability of SOF oral granules</outcome_measure>
      <outcome_measure>Treatment Phase: growth and development measurements as assessed by height</outcome_measure>
      <outcome_measure>Treatment Phase: growth and development measurements as assessed by weight</outcome_measure>
      <outcome_measure>Treatment Phase: growth and development measurements as assessed by Tanner Stage Assessment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>Belgium</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>New Zealand</country>
      <country>Russian Federation</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Washington</state>
      <state>West Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02175758</url>
  </study>
  <study rank="53">
    <nct_id>NCT02220998</nct_id>
    <title>Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF/VEL</intervention>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>269</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-342-1139</other_id>
    </other_ids>
    <first_received>August 18, 2014</first_received>
    <start_date>September 2014</start_date>
    <completion_date>September 2015</completion_date>
    <last_updated>September 16, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ASTRAL-2</acronym>
    <primary_completion_date>July 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with HCV RNA &lt; LLOQ on treatment</outcome_measure>
      <outcome_measure>HCV RNA change from baseline</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02220998</url>
  </study>
  <study rank="54">
    <nct_id>NCT01667731</nct_id>
    <title>Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Human Immunodeficiency Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>224</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0123</other_id>
    </other_ids>
    <first_received>August 9, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>February 2014</completion_date>
    <last_updated>November 14, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>November 14, 2014</firstreceived_results_date>
    <primary_completion_date>November 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 1</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 2</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 4</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 6</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 8</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing On-treatment Virologic Failure</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Texas</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01667731</url>
  </study>
  <study rank="55">
    <nct_id>NCT01701401</nct_id>
    <title>Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>870</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-0102</other_id>
      <other_id>2012-003387-43</other_id>
    </other_ids>
    <first_received>October 2, 2012</first_received>
    <start_date>September 2012</start_date>
    <completion_date>April 2014</completion_date>
    <last_updated>March 17, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>March 17, 2015</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Study Drug (SVR12)</outcome_measure>
      <outcome_measure>Incidence of Adverse Events Leading to Permanent Discontinuation From Any Study Drug</outcome_measure>
      <outcome_measure>Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Study Drug</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 2</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ at Week 8</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 2</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 4</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 8</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01701401</url>
  </study>
  <study rank="56">
    <nct_id>NCT02600351</nct_id>
    <title>Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-1746</other_id>
    </other_ids>
    <first_received>November 5, 2015</first_received>
    <start_date>November 2015</start_date>
    <completion_date>April 2017</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR) 12 weeks after cessation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Proportion of participants who discontinued from study treatment for an adverse event</outcome_measure>
      <outcome_measure>Proportion of participants with HCV RNA &lt; the lower limit of quantitation (LLOQ) at 4 and 24 weeks posttreatment</outcome_measure>
      <outcome_measure>Proportion of participants with viral breakthrough</outcome_measure>
      <outcome_measure>Proportion of participants with viral relapse</outcome_measure>
      <outcome_measure>Proportion of participants with emerging resistance</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New Jersey</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02600351</url>
  </study>
  <study rank="57">
    <nct_id>NCT01565889</nct_id>
    <title>Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">EFV/FTC/TDF</intervention>
      <intervention type="Drug">EFV</intervention>
      <intervention type="Drug">ZDV/3TC</intervention>
      <intervention type="Drug">ATV</intervention>
      <intervention type="Drug">Ritonavir</intervention>
      <intervention type="Drug">FTC/TDF</intervention>
      <intervention type="Drug">DRV</intervention>
      <intervention type="Drug">RAL</intervention>
      <intervention type="Drug">PEG</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>52</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P7977-1910</other_id>
    </other_ids>
    <first_received>March 27, 2012</first_received>
    <start_date>March 2012</start_date>
    <completion_date>November 2013</completion_date>
    <last_updated>September 25, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>August 28, 2014</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Part A: Plasma Pharmacokinetics of SOF, EFV, Tenofovir (TFV), and FTC: AUCtau at Day 7</outcome_measure>
      <outcome_measure>Part A: Plasma Pharmacokinetics of SOF, EFV, TFV, and FTC: Cmax at Day 7</outcome_measure>
      <outcome_measure>Part B: Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)</outcome_measure>
      <outcome_measure>Part B: Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Part B: Percentage of Participants Experiencing Viral Breakthrough or Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01565889</url>
  </study>
  <study rank="58">
    <nct_id>NCT01260350</nct_id>
    <title>Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">PEG</intervention>
      <intervention type="Drug">LDV</intervention>
      <intervention type="Drug">GS-9669</intervention>
      <intervention type="Drug">LDV/SOF</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>292</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P7977-0523</other_id>
      <other_id>Medsafe</other_id>
    </other_ids>
    <first_received>December 13, 2010</first_received>
    <start_date>December 2010</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>November 7, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>November 7, 2014</firstreceived_results_date>
    <primary_completion_date>October 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Who Experienced Adverse Events</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks Following Completion of Treatment (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LOD at Week 6</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LOD at Week 8</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LOD at Week 12</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 6</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 8</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>New Zealand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01260350</url>
  </study>
  <study rank="59">
    <nct_id>NCT02201953</nct_id>
    <title>Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF/VEL</intervention>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>558</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-342-1140</other_id>
      <other_id>2014-001682-27</other_id>
    </other_ids>
    <first_received>July 24, 2014</first_received>
    <start_date>July 2014</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>December 8, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ASTRAL-3</acronym>
    <primary_completion_date>September 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with HCV RNA &lt; LLOQ on treatment</outcome_measure>
      <outcome_measure>HCV RNA change from baseline</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02201953</url>
  </study>
  <study rank="60">
    <nct_id>NCT01858766</nct_id>
    <title>Safety and Efficacy of Sofosbuvir Plus GS-5816 With or Without Ribavirin in Treatment-naive Subjects With Chronic HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">GS-5816</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>378</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-342-0102</other_id>
    </other_ids>
    <first_received>May 10, 2013</first_received>
    <start_date>April 2013</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>February 25, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of adverse events leading to permanent discontinuation of study drug</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR) at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01858766</url>
  </study>
  <study rank="61">
    <nct_id>NCT01909804</nct_id>
    <title>Safety and Efficacy of Sofosbuvir Plus GS-5816 With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">GS-5816</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>323</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-342-0109</other_id>
    </other_ids>
    <first_received>July 17, 2013</first_received>
    <start_date>June 2013</start_date>
    <completion_date>August 2014</completion_date>
    <last_updated>February 25, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of adverse events leading to permanent discontinuation of study drug</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR) at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01909804</url>
  </study>
  <study rank="62">
    <nct_id>NCT01958281</nct_id>
    <title>Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF 100 mg</intervention>
      <intervention type="Drug">SOF 400 mg</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">LDV/SOF</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>35</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0154</other_id>
      <other_id>2013-002897-30</other_id>
    </other_ids>
    <first_received>October 6, 2013</first_received>
    <start_date>October 2013</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>November 12, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of treatment (SVR12)</outcome_measure>
      <outcome_measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</outcome_measure>
      <outcome_measure>Plasma pharmacokinetics (PK) of sofosbuvir and its metabolites, and RBV, including AUCtau, Cmax, and Ctau</outcome_measure>
      <outcome_measure>Plasma pharmacokinetics (PK) of sofosbuvir and its metabolites, and RBV, including AUClast, Clast, Tmax, Tlast, λz, and t1/2</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response 4 and 24 weeks after discontinuation of treatment (SVR4 and SVR 24)</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Argentina</country>
      <country>Austria</country>
      <country>Germany</country>
      <country>Netherlands</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Michigan</state>
      <state>New York</state>
      <state>Texas</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01958281</url>
  </study>
  <study rank="63">
    <nct_id>NCT02175966</nct_id>
    <title>Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DCV/ASV/BMS-791325</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Peginterferon α-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI443-131</other_id>
    </other_ids>
    <first_received>June 25, 2014</first_received>
    <start_date>July 2014</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>December 8, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>FOURward</acronym>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of treated subjects with SVR12, defined as HCV RNA &lt; LLOQ target detected or target not detected (LLOQ TD/TND) for each treatment arm</outcome_measure>
      <outcome_measure>On-treatment safety, as measured by frequency of deaths, SAEs, discontinuations due to AEs, and Grade 3/4 laboratory abnormalities (hematologic and liver function, based on DAIDs criteria) by each arm and overall</outcome_measure>
      <outcome_measure>Proportion of subjects in each arm who achieve HCV RNA &lt;LLOQ TD/TND</outcome_measure>
      <outcome_measure>Proportion of subjects in each arm who achieve HCV RNA &lt;LLOQ TND</outcome_measure>
      <outcome_measure>Proportion of subjects in each arm achieving SVR12 associated with HCV geno subtype 1a vs 1b</outcome_measure>
      <outcome_measure>Proportion of subjects in each arm achieving SVR12 associated with interleukin-28B (IL28B) rs12979860 SNP status (CC genotype or non-CC genotype)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02175966</url>
  </study>
  <study rank="64">
    <nct_id>NCT01682720</nct_id>
    <title>Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">Placebo to match SOF</intervention>
      <intervention type="Drug">Placebo to match RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>421</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0133</other_id>
      <other_id>2012-001942-16</other_id>
    </other_ids>
    <first_received>September 5, 2012</first_received>
    <start_date>September 2012</start_date>
    <completion_date>January 2014</completion_date>
    <last_updated>October 8, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>October 2, 2014</firstreceived_results_date>
    <primary_completion_date>October 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Adverse Events Leading to Permanent Discontinuation of Study Drug(s)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Viral Breakthrough or Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
      <country>Estonia</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Netherlands</country>
      <country>Poland</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01682720</url>
  </study>
  <study rank="65">
    <nct_id>NCT02226549</nct_id>
    <title>Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">VDV</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>47</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-1512</other_id>
    </other_ids>
    <first_received>August 25, 2014</first_received>
    <start_date>July 2014</start_date>
    <completion_date>February 2015</completion_date>
    <last_updated>February 19, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of any adverse event leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response 4 weeks after discontinuation of therapy (SVR4)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02226549</url>
  </study>
  <study rank="66">
    <nct_id>NCT01987453</nct_id>
    <title>Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Subjects With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-1118</other_id>
      <other_id>2014-001245-24</other_id>
    </other_ids>
    <first_received>November 12, 2013</first_received>
    <start_date>November 2013</start_date>
    <completion_date>February 2016</completion_date>
    <last_updated>November 23, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of adverse events leading to permanent discontinuation of study drug</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR) at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with HCV RNA &lt; LLOQ while on treatment</outcome_measure>
      <outcome_measure>Change in HCV RNA from Baseline</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>France</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01987453</url>
  </study>
  <study rank="67">
    <nct_id>NCT02469012</nct_id>
    <title>Neurocognitive Performance and Emotional State in HCV Patients With IFN-free Antiviral Therapy</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Combination #1</intervention>
      <intervention type="Drug">Combination #2</intervention>
      <intervention type="Drug">Combination #3</intervention>
      <intervention type="Drug">Combination #4</intervention>
      <intervention type="Drug">Combination #5</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Wuerzburg</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Screening</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>228/14</other_id>
    </other_ids>
    <first_received>May 5, 2015</first_received>
    <start_date>October 2014</start_date>
    <completion_date>April 2017</completion_date>
    <last_updated>June 8, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>IFNfreeCOG</acronym>
    <primary_completion_date>October 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Neurocognitive Performance (computerized TAP - Test Battery for Attentional Performance)</outcome_measure>
      <outcome_measure>Change in Fatigue (Fatigue Impact Scale - FIS-D, questionnaire)</outcome_measure>
      <outcome_measure>Change in Health-Related Quality of Life (SF-36, questionnaire)</outcome_measure>
      <outcome_measure>Change in Emotional State (Hospital Anxiety and Depression Scale HADS, questionnaire)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02469012</url>
  </study>
  <study rank="68">
    <nct_id>NCT02605304</nct_id>
    <title>12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV-1 Infection</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ledipasvir/sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AIDS Clinical Trials Group</lead_sponsor>
      <collaborator>National Institute of Allergy and Infectious Diseases (NIAID)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ACTG A5348</other_id>
      <other_id>UM1AI068636</other_id>
    </other_ids>
    <first_received>November 12, 2015</first_received>
    <start_date>November 2015</start_date>
    <completion_date>May 2017</completion_date>
    <last_updated>November 12, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response 12 weeks after HCV antiviral therapy (SVR12)</outcome_measure>
      <outcome_measure>Occurrence of Grade 3 or higher AE, serious AE (SAE), or AE reported as the reason for permanent discontinuation of study treatment</outcome_measure>
      <outcome_measure>Renal toxicity</outcome_measure>
      <outcome_measure>Sustained Virologic Response at 4 weeks after treatment discontinuation (SVR4)</outcome_measure>
      <outcome_measure>Sustained Virologic Response at 24 weeks after treatment discontinuation (SVR24)</outcome_measure>
      <outcome_measure>HCV RNA &lt;LLOQ (lower limit of quantification)</outcome_measure>
      <outcome_measure>HIV-1 RNA &gt; 50 copies/mL</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02605304</url>
  </study>
  <study rank="69">
    <nct_id>NCT02300103</nct_id>
    <title>Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF/VEL</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-342-1553</other_id>
    </other_ids>
    <first_received>November 20, 2014</first_received>
    <start_date>December 2014</start_date>
    <completion_date>September 2016</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with HCV RNA &lt; LLOQ on-treatment</outcome_measure>
      <outcome_measure>HCV RNA change from baseline</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02300103</url>
  </study>
  <study rank="70">
    <nct_id>NCT01975675</nct_id>
    <title>Efficacy and Safety of Sofosbuvir/Ledipasvir ± Ribavirin in Japanese Participants With Chronic Genotype 1 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>341</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-0113</other_id>
    </other_ids>
    <first_received>October 29, 2013</first_received>
    <start_date>October 2013</start_date>
    <completion_date>August 2014</completion_date>
    <last_updated>June 4, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>June 4, 2015</firstreceived_results_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12), Treatment-naive, Noncirrhotic Participants</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Virologic Failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01975675</url>
  </study>
  <study rank="71">
    <nct_id>NCT02536313</nct_id>
    <title>Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF/VEL/GS-9857</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>49</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-367-1871</other_id>
    </other_ids>
    <first_received>August 27, 2015</first_received>
    <start_date>July 2015</start_date>
    <completion_date>June 2016</completion_date>
    <last_updated>November 6, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR) 12 weeks after cessation of treatment (SVR12)</outcome_measure>
      <outcome_measure>Incidence of any adverse event (AE) leading to permanent discontinuation of study drug(s).</outcome_measure>
      <outcome_measure>Proportion of participants with SVR at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>The proportion of participants with HCV RNA &lt; LLOQ on treatment</outcome_measure>
      <outcome_measure>HCV RNA change from Baseline/Day 1</outcome_measure>
      <outcome_measure>The proportion of participants with virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02536313</url>
  </study>
  <study rank="72">
    <nct_id>NCT02214420</nct_id>
    <title>SMV + SOF With/Without RBV for IFN-II Patients With CHC</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>SC Liver Research Consortium, LLC</lead_sponsor>
      <collaborator>Janssen, LP</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>PJPIIS-01-14</other_id>
    </other_ids>
    <first_received>August 8, 2014</first_received>
    <start_date>October 2014</start_date>
    <completion_date>February 2017</completion_date>
    <last_updated>November 27, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Viral Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>New York</state>
      <state>Utah</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02214420</url>
  </study>
  <study rank="73">
    <nct_id>NCT01726517</nct_id>
    <title>Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-0118</other_id>
    </other_ids>
    <first_received>November 10, 2012</first_received>
    <start_date>October 2012</start_date>
    <completion_date>January 2014</completion_date>
    <last_updated>November 7, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>November 7, 2014</firstreceived_results_date>
    <primary_completion_date>July 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)</outcome_measure>
      <outcome_measure>Percentage of Participants With SVR at 2, 4, 8, and 24 Weeks After Discontinuation of Therapy (SVR2, SVR4, SVR8, and SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Viral Breakthrough or Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01726517</url>
  </study>
  <study rank="74">
    <nct_id>NCT02472886</nct_id>
    <title>Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection.</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>153</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-1463</other_id>
      <other_id>2015-000690-13</other_id>
    </other_ids>
    <first_received>June 12, 2015</first_received>
    <start_date>June 2015</start_date>
    <completion_date>July 2016</completion_date>
    <last_updated>November 6, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of any adverse events leading to permanent discontinuation of study drug</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR) at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with HCV RNA &lt; LLOQ on treatment</outcome_measure>
      <outcome_measure>HCV RNA change from Day 1</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
      <outcome_measure>Proportion of HIV/HCV coinfected participants that maintain HIV-1 RNA &lt; 50 copies/mL while on HCV treatment and at Posttreatment Week 4</outcome_measure>
      <outcome_measure>For HIV/HCV coinfected participants, change from baseline in CD4 T-cell count at the end of treatment and Posttreatment Week 4</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Estonia</country>
      <country>Russian Federation</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02472886</url>
  </study>
  <study rank="75">
    <nct_id>NCT01625338</nct_id>
    <title>Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">Peg-IFN</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>534</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0109</other_id>
      <other_id>2012-000571-16</other_id>
    </other_ids>
    <first_received>June 7, 2012</first_received>
    <start_date>June 2012</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>October 9, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>October 9, 2015</firstreceived_results_date>
    <primary_completion_date>October 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event</outcome_measure>
      <outcome_measure>Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Virologic Failure</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>Czech Republic</country>
      <country>Estonia</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Netherlands</country>
      <country>New Zealand</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01625338</url>
  </study>
  <study rank="76">
    <nct_id>NCT02249182</nct_id>
    <title>Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/-Ribavirin in Adolescents and Children With Chronic HCV-Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">Placebo to match LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-1116</other_id>
    </other_ids>
    <first_received>September 23, 2014</first_received>
    <start_date>November 2014</start_date>
    <completion_date>October 2017</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>For the PK Lead-in Phase, PK parameters of GS-331007, SOF, and LDV as measured by AUCtau to determine the appropriate LDV/SOF FDC dose.</outcome_measure>
      <outcome_measure>For the Treatment Phase, any adverse event leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>For the PK Lead-in Phase, serum HCV RNA values and change from baseline</outcome_measure>
      <outcome_measure>For the PK Lead-in Phase, adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>For the Treatment Phase, growth and development as measured by height</outcome_measure>
      <outcome_measure>For the Treatment Phase, growth and development as measured by weight</outcome_measure>
      <outcome_measure>For the Treatment Phase, growth and development as measured by Tanner Stage Assessment</outcome_measure>
      <outcome_measure>For the Treatment Phase, proportion of participants with sustained virologic response (SVR) at 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>For the Treatment Phase, proportion of participants with sustained virologic response (SVR) at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>For the Treatment Phase, proportion of participants experiencing viral breakthrough</outcome_measure>
      <outcome_measure>For the Treatment Phase, proportion of participants experiencing viral relapse</outcome_measure>
      <outcome_measure>For the Treatment Phase, HCV RNA change from baseline</outcome_measure>
      <outcome_measure>For the Treatment Phase, alanine aminotransferase (ALT) normalization</outcome_measure>
      <outcome_measure>For the Treatment Phase, viral kinetic parameters</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>New Zealand</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Indiana</state>
      <state>Kentucky</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>Nebraska</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Washington</state>
      <state>West Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02249182</url>
  </study>
  <study rank="77">
    <nct_id>NCT01938430</nct_id>
    <title>Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>339</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-0123</other_id>
    </other_ids>
    <first_received>September 5, 2013</first_received>
    <start_date>September 2013</start_date>
    <completion_date>March 2015</completion_date>
    <last_updated>November 4, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR12), defined as HCV RNA &lt; lower limit of quantitation (LLOQ) 12 weeks after last dose of study drug</outcome_measure>
      <outcome_measure>Proportion of participants who discontinue study drug due to an adverse event</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR) at 2, 4, 8 and 24 weeks after discontinuation of therapy (SVR2, SVR4, SVR8 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants who have HCV RNA &lt; LLOQ by visit while on treatment</outcome_measure>
      <outcome_measure>HCV RNA levels and change from Day 1 through Week 8</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
      <outcome_measure>Change in model for end-stage liver disease (MELD) and Child-Pugh-Turcotte (CPT) scores</outcome_measure>
      <outcome_measure>Proportion of participants with post-transplant virologic response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Kansas</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01938430</url>
  </study>
  <study rank="78">
    <nct_id>NCT02010255</nct_id>
    <title>Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>334</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-0124</other_id>
      <other_id>2013-002802-30</other_id>
    </other_ids>
    <first_received>December 9, 2013</first_received>
    <start_date>January 2014</start_date>
    <completion_date>August 2015</completion_date>
    <last_updated>September 9, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after last dose of study drug (SVR12)</outcome_measure>
      <outcome_measure>Proportion of participants who discontinue study drug due to an adverse event</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR) 2, 4, 8, and 24 weeks after last dose of study drug (SVR2, SVR4, SVR8 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants who have HCV RNA &lt; LLOQ by visit while on treatment</outcome_measure>
      <outcome_measure>HCV RNA levels and change from Day 1 through Week 8</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
      <outcome_measure>Change in model for end-stage liver disease (MELD) and Child-Pugh-Turcotte (CPT) scores</outcome_measure>
      <outcome_measure>Proportion of participants with post-transplant virologic response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Netherlands</country>
      <country>New Zealand</country>
      <country>Spain</country>
      <country>Switzerland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02010255</url>
  </study>
  <study rank="79">
    <nct_id>NCT01965535</nct_id>
    <title>Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">Placebo to match LDV/SOF</intervention>
      <intervention type="Drug">Placebo to match RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>155</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-0121</other_id>
      <other_id>2013-002296-17</other_id>
    </other_ids>
    <first_received>October 16, 2013</first_received>
    <start_date>October 2013</start_date>
    <completion_date>November 2014</completion_date>
    <last_updated>August 27, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>August 27, 2015</firstreceived_results_date>
    <primary_completion_date>August 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ (ie, &lt; 25 IU/mL) at Weeks 1, 2, 4, 8, 12, and 24</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Weeks 1, 2, 4, 8, and 12</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01965535</url>
  </study>
  <study rank="80">
    <nct_id>NCT01826981</nct_id>
    <title>Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Subjects With Chronic Genotype 1, 2, 3, or 6 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF FDC</intervention>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">PEG</intervention>
      <intervention type="Drug">GS-9669</intervention>
      <intervention type="Drug">GS-5816</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>362</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-0122</other_id>
    </other_ids>
    <first_received>April 1, 2013</first_received>
    <start_date>April 2013</start_date>
    <completion_date>May 2015</completion_date>
    <last_updated>June 3, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Proportion of participants with adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with SVR through posttreatment Week 24</outcome_measure>
      <outcome_measure>Proportion of participants with on-treatment virologic failure and relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>New Zealand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01826981</url>
  </study>
  <study rank="81">
    <nct_id>NCT02064049</nct_id>
    <title>Surveillance and Treatment of Prisoners With Hepatitis C</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kirby Institute</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>650</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VHCRP1302</other_id>
    </other_ids>
    <first_received>February 12, 2014</first_received>
    <start_date>October 2014</start_date>
    <completion_date>December 2017</completion_date>
    <last_updated>August 31, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>SToP-C</acronym>
    <primary_completion_date>December 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Hepatitis C virus (HCV) incidence</outcome_measure>
      <outcome_measure>Hepatitis C virus prevalence</outcome_measure>
      <outcome_measure>SVR12</outcome_measure>
      <outcome_measure>ETR</outcome_measure>
      <outcome_measure>Rapid Virological Response (RVR)</outcome_measure>
      <outcome_measure>Very rapid virological response (vRVR)</outcome_measure>
      <outcome_measure>Treatment adherence</outcome_measure>
      <outcome_measure>Number of patients with adverse events</outcome_measure>
      <outcome_measure>Treatment uptake</outcome_measure>
      <outcome_measure>On-treatment change in illicit drug use</outcome_measure>
      <outcome_measure>HCV reinfection rate</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02064049</url>
  </study>
  <study rank="82">
    <nct_id>NCT02482077</nct_id>
    <title>Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF+RBV</intervention>
      <intervention type="Drug">SOF+DCV</intervention>
      <intervention type="Drug">LDV/SOF</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Humanity &amp; Healthy GI and Liver Centre</lead_sponsor>
      <collaborator>Beijing 302 Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>H&amp;H_HCV G2 Study</other_id>
    </other_ids>
    <first_received>June 23, 2015</first_received>
    <start_date>January 2015</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>June 23, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy</outcome_measure>
      <outcome_measure>Proportion of participants with adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with unquantifiable HCV viral load at specified time points during and after treatment</outcome_measure>
      <outcome_measure>HCV RNA levels and change during and after treatment.</outcome_measure>
      <outcome_measure>Proportion of participants with on-treatment virologic breakthrough and relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02482077</url>
  </study>
  <study rank="83">
    <nct_id>NCT02128217</nct_id>
    <title>Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV-1 Infection</condition>
      <condition>Hepatitis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ledipasvir/Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AIDS Clinical Trials Group</lead_sponsor>
      <collaborator>National Institute of Allergy and Infectious Diseases (NIAID)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ACTG A5327</other_id>
      <other_id>UM1AI068636</other_id>
    </other_ids>
    <first_received>April 29, 2014</first_received>
    <start_date>April 2014</start_date>
    <completion_date>November 2016</completion_date>
    <last_updated>October 5, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>SWIFT-C</acronym>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR12 defined as HCV RNA undetectable (&lt;LLOQ TND) of the assay at 12 weeks after date of last dose of study treatment.</outcome_measure>
      <outcome_measure>Occurrence of a Grade ≥ 2 adverse event (AE: diagnosis, sign, symptom or laboratory abnormality), Serious AE according to ICH criteria, or treatment-limiting AE (ie, an AE reported as the reason for permanent discontinuation of study treatment)</outcome_measure>
      <outcome_measure>HCV RNA undetectable during study treatment</outcome_measure>
      <outcome_measure>HCV RNA undetectable after end of study treatment</outcome_measure>
      <outcome_measure>HCV virologic relapse</outcome_measure>
      <outcome_measure>Development of SOF or LDV-associated resistance mutations</outcome_measure>
      <outcome_measure>Occurrence of each type of adverse event</outcome_measure>
      <outcome_measure>Change in HIV-1 RNA from last measurement prior to start of study treatment</outcome_measure>
      <outcome_measure>Change in CD4+ cell count from last measurement prior to start of study treatment.</outcome_measure>
      <outcome_measure>Self-reported adherence to SOF</outcome_measure>
      <outcome_measure>Self-reported adherence to RBV</outcome_measure>
      <outcome_measure>Adherence as measured by SOF pill count</outcome_measure>
      <outcome_measure>Adherence as measured by RBV pill count</outcome_measure>
      <outcome_measure>Self-reported adherence to LDV/SOF</outcome_measure>
      <outcome_measure>Adherence as measured by LDV/SOF pill count</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02128217</url>
  </study>
  <study rank="84">
    <nct_id>NCT01939197</nct_id>
    <title>A Two Part, Open-label Study to Evaluate the Safety and Effectiveness of ABT-450/r/ABT-267 or ABT-450/r/ABT-267 and ABT-333 Given With or Without a Drug Called Ribavirin in People With Both Hepatitis C Virus Genotype 1 or 4 Infection and Human Immunodeficiency Virus, Type 1 Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
      <condition>Human Immunodeficiency Virus Infection</condition>
      <condition>Chronic Hepatitis C</condition>
      <condition>Compensated Cirrhosis and Non-cirrhotics</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450/r/ABT-267</intervention>
      <intervention type="Drug">ABT-333</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>320</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M14-004</other_id>
      <other_id>2012-005143-24</other_id>
    </other_ids>
    <first_received>September 6, 2013</first_received>
    <start_date>August 2013</start_date>
    <completion_date>September 2016</completion_date>
    <last_updated>October 3, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>TURQUOISE-I</acronym>
    <primary_completion_date>July 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of subjects in genotype 1 Analysis Group 1 in Part 2 achieving sustained virologic response 12 weeks post-treatment (SVR12) compared to the historical SVR12 rate for sofosbuvir plus ribavirin as reported in the PHOTON-1 study</outcome_measure>
      <outcome_measure>The percentage of subjects in genotype 1 Analysis Group 2 of Part 2 achieving sustained virologic response 12 weeks post-treatment (SVR12) compared to the historical rate for sofosbuvir plus ribavirin</outcome_measure>
      <outcome_measure>The percentage of Part 1a subjects achieving sustained virologic response 12 weeks post-treatment (SVR12) in the 24-week treatment group compared to the 12-week treatment group using Fisher's exact test</outcome_measure>
      <outcome_measure>The percentage of subjects of Part 1b subjects achieving sustained virologic response 12 weeks post-treatment (SVR12) in the darunavir once-daily arm compared to the darunavir twice-daily arm using Fisher's exact test</outcome_measure>
      <outcome_measure>The percentage of Part 1b subjects achieving sustained virologic response 12 weeks post-treatment (SVR12)</outcome_measure>
      <outcome_measure>The percentage of Part 2 GT 1b cirrhotic subjects achieving sustained virologic response 12 weeks post-treatment (SVR12) in Arm F (without ribavirin) compared to Arm G (with ribavirin) using Fisher's exact test</outcome_measure>
      <outcome_measure>The percentage of genotype 4 subjects in Part 2 achieving sustained virologic response 12 weeks post-treatment (SVR12) by arm and overall</outcome_measure>
      <outcome_measure>Percentage of subjects with on treatment Hepatitis C Virus virologic failure during the Treatment Period for each arm in Part 1, set of all subjects in Part 1b, the genotype 1 Analysis Group 1 and 2 in Part 2, the GT4 Analysis Group by arm and overall</outcome_measure>
      <outcome_measure>The percentage of subjects with Hepatitis C Virus post-treatment relapse (analyses performed as described for secondary endpoint 7).</outcome_measure>
      <outcome_measure>Percentage of subjects with plasma HIV-1 RNA suppression at end of treatment and 12 weeks post-treatment (analyses performed as described for secondary endpoint 7) and comparison of the darunavir once-daily and twice-daily arms in Part 1b</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Michigan</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01939197</url>
  </study>
  <study rank="85">
    <nct_id>NCT02480686</nct_id>
    <title>Neutrino Regimen for Treatment-experienced HCV GT1 Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF+PEG+RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Humanity &amp; Healthy GI and Liver Centre</lead_sponsor>
      <collaborator>Beijing 302 Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>H&amp;H_Neutrino Therapy</other_id>
    </other_ids>
    <first_received>June 21, 2015</first_received>
    <start_date>January 2015</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>June 22, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Proportion of participants with adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Change in HCV RNA From Baseline to Week 12</outcome_measure>
      <outcome_measure>Proportion of participants with on-treatment virologic breakthrough and relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02480686</url>
  </study>
  <study rank="86">
    <nct_id>NCT02468648</nct_id>
    <title>Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">GS-5816</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>140</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>150143</other_id>
      <other_id>15-DK-0143</other_id>
    </other_ids>
    <first_received>June 9, 2015</first_received>
    <start_date>June 2015</start_date>
    <completion_date>July 2017</completion_date>
    <last_updated>September 12, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary endpoints will be changes in interferon stimulated gene and protein expression in the liver and changes in HCV RNA levels in liver and serum between baseline and 4 weeks.</outcome_measure>
      <outcome_measure>Proportion who achieve SVR12 stratified by viral genotype</outcome_measure>
      <outcome_measure>Secondary endpoints will be safety and rates of sustained virologic response 24 weeks off therapy</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02468648</url>
  </study>
  <study rank="87">
    <nct_id>NCT01441180</nct_id>
    <title>GS-7977 With Ribavirin for Hepatitis C (SPARE)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GS7977</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>110258</other_id>
      <other_id>11-I-0258</other_id>
    </other_ids>
    <first_received>September 24, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>September 25, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>April 23, 2014</firstreceived_results_date>
    <primary_completion_date>March 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Participants With Adverse Events</outcome_measure>
      <outcome_measure>Sustained Virologic Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01441180</url>
  </study>
  <study rank="88">
    <nct_id>NCT02125500</nct_id>
    <title>Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Viral Hepatitis C</condition>
      <condition>HIV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir/Ledipasvir fixed dose</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>68</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRS HC31 SOFTRIH</other_id>
    </other_ids>
    <first_received>April 24, 2014</first_received>
    <start_date>September 2014</start_date>
    <completion_date>November 2015</completion_date>
    <last_updated>December 9, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response 12 weeks after discontinuation of therapy (SVR12), i.e. at week 36.</outcome_measure>
      <outcome_measure>Adverse clinical and biological events that occur during the treatment and up to 24 weeks after the end of the treatment</outcome_measure>
      <outcome_measure>Number and causes of poor adherence and treatment interruptions</outcome_measure>
      <outcome_measure>SVR rate 24 weeks (i.e. W48) after the end of treatment and according to the HCV sub-type</outcome_measure>
      <outcome_measure>Number of patients with HCV resistance mutations to Sofosbuvir and/or Ledipasvir</outcome_measure>
      <outcome_measure>HCV viral load</outcome_measure>
      <outcome_measure>Plasma HIV RNA levels</outcome_measure>
      <outcome_measure>Assess drug-drug interactions between HCV et HIV drugs</outcome_measure>
      <outcome_measure>Patient's reported outcomes evaluation</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02125500</url>
  </study>
  <study rank="89">
    <nct_id>NCT02583685</nct_id>
    <title>Switching Regimen in Treating Cirrhotic HCV GT1b Subjects</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PR4 + LDV/SOF + ASV 4 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + SMV 4 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + ASV 6 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + SMV 6 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + ASV 8 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + SMV 8 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + ASV 12 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + SMV 12 wk</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Humanity &amp; Healthy GI and Liver Centre</lead_sponsor>
      <collaborator>Beijing 302 Hospital</collaborator>
      <collaborator>Nanfang Hospital of Southern Medical University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>160</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>H&amp;H_SWITCH-1</other_id>
    </other_ids>
    <first_received>October 12, 2015</first_received>
    <start_date>May 2015</start_date>
    <completion_date>September 2016</completion_date>
    <last_updated>October 20, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>SWITCH-1</acronym>
    <primary_completion_date>September 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks (SVR12) after discontinuation of therapy</outcome_measure>
      <outcome_measure>Proportion of participants with adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with unquantifiable HCV viral load at specified time points during and after treatment</outcome_measure>
      <outcome_measure>Treatment adherence</outcome_measure>
      <outcome_measure>Change in health related quality of life evaluated with questionnaires</outcome_measure>
      <outcome_measure>Change in mental health evaluated with questionnaires</outcome_measure>
      <outcome_measure>Liver disease progression</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02583685</url>
  </study>
  <study rank="90">
    <nct_id>NCT02250807</nct_id>
    <title>Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Genotype 4 Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR105429</other_id>
      <other_id>TMC435HPC3021</other_id>
      <other_id>2014-003446-27</other_id>
    </other_ids>
    <first_received>September 24, 2014</first_received>
    <start_date>January 2015</start_date>
    <completion_date>January 2016</completion_date>
    <last_updated>September 25, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Subjects With Sustained Virologic Response (SVR 12) at Week 12 After End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Percentage of Subjects With Sustained Virologic Response at Week 4 (SVR 4) and 24 (SVR 24) After EOT</outcome_measure>
      <outcome_measure>Percentage of Subjects With On-treatment Virologic Response of Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)</outcome_measure>
      <outcome_measure>Percentage of Subjects With on-treatment failure along with Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Subjects With Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02250807</url>
  </study>
  <study rank="91">
    <nct_id>NCT02485262</nct_id>
    <title>Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir and simeprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Arrowhead Regional Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>340</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>1234</other_id>
      <other_id>14-25</other_id>
    </other_ids>
    <first_received>June 19, 2015</first_received>
    <start_date>November 2013</start_date>
    <completion_date>November 2016</completion_date>
    <last_updated>June 29, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR 12</outcome_measure>
      <outcome_measure>Safety and Tolerability as measured by the number of participants with AEs, Change in baseline laboratory results</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02485262</url>
  </study>
  <study rank="92">
    <nct_id>NCT02555943</nct_id>
    <title>DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
      <condition>HBV Coinfection</condition>
      <condition>Hepatitis B Reactivation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ledipasvir/Sofosbuvir</intervention>
      <intervention type="Drug">Sofosbuvir and Daclatasvir</intervention>
      <intervention type="Drug">Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir</intervention>
      <intervention type="Drug">Entecavir</intervention>
      <intervention type="Drug">Tenofovir disoproxil</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Humanity &amp; Healthy GI and Liver Centre</lead_sponsor>
      <collaborator>Beijing 302 Hospital</collaborator>
      <collaborator>Nanfang Hospital of Southern Medical University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>H&amp;H_DASCO</other_id>
    </other_ids>
    <first_received>September 20, 2015</first_received>
    <start_date>February 2015</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>September 20, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>DASCO</acronym>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants who experience virological breakthrough</outcome_measure>
      <outcome_measure>Proportion of participants who experience virological rebound</outcome_measure>
      <outcome_measure>Proportion of participant who experience biochemical rebound</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02555943</url>
  </study>
  <study rank="93">
    <nct_id>NCT02057003</nct_id>
    <title>Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Human Immunodeficiency Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DAA against HCV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Valme University Hospital</lead_sponsor>
      <collaborator>Hospital Universitario Reina Sofia</collaborator>
      <collaborator>Hospital Universitario Virgen de la Victoria</collaborator>
      <collaborator>Hospital Universitario de la Princesa</collaborator>
      <collaborator>Hospitales Universitarios Virgen del Rocío</collaborator>
      <collaborator>Hospital Universitario Carlos Haya</collaborator>
      <collaborator>Hospital Torrecárdenas</collaborator>
      <collaborator>Complejo Hospitalario Universitario de Huelva</collaborator>
      <collaborator>Hospital Puerta del Mar</collaborator>
      <collaborator>Hospital Universitario Virgen Macarena</collaborator>
      <collaborator>Hospital de La Línea</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>HEPAVIR-DAA</other_id>
    </other_ids>
    <first_received>January 6, 2014</first_received>
    <start_date>January 2012</start_date>
    <completion_date>December 2017</completion_date>
    <last_updated>November 10, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of patients who achieve SVR to DAA-based therapy as measure of efficacy</outcome_measure>
      <outcome_measure>Number of patients who develop severe adverse events as measure of safety</outcome_measure>
      <outcome_measure>Number of patients who achieve SVR to a BOC-based regimen as compared to numbers of patients who achieve SVR to a TVR-based regimen.</outcome_measure>
      <outcome_measure>Number of patients who reach undetectable HCV-RNA at week 4 of PI-based therapy as a measure of on-treatment response to therapy.</outcome_measure>
      <outcome_measure>Number of patients who develop adverse events during a BOC-based regimen as compared to numbers of patients who develop adverse events during a TVR-based regimen.</outcome_measure>
      <outcome_measure>Number of patients who achieve SVR to an interferon-free regimen.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02057003</url>
  </study>
  <study rank="94">
    <nct_id>NCT02201901</nct_id>
    <title>Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF/VEL</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>268</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-342-1137</other_id>
    </other_ids>
    <first_received>July 24, 2014</first_received>
    <start_date>July 2014</start_date>
    <completion_date>November 2015</completion_date>
    <last_updated>December 8, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ASTRAL-4</acronym>
    <primary_completion_date>August 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with HCV RNA &lt; LLOQ on treatment</outcome_measure>
      <outcome_measure>Model for end-stage liver disease (MELD) and CPT score changes from baseline</outcome_measure>
      <outcome_measure>HCV RNA change from baseline</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Kansas</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02201901</url>
  </study>
  <study rank="95">
    <nct_id>NCT02378935</nct_id>
    <title>Safety and Efficacy of GS-9857 Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GS-9857</intervention>
      <intervention type="Drug">SOF/VEL</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>205</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-367-1168</other_id>
    </other_ids>
    <first_received>February 27, 2015</first_received>
    <start_date>February 2015</start_date>
    <completion_date>April 2016</completion_date>
    <last_updated>September 22, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of any adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with HCV RNA &lt; LLOQ on treatment</outcome_measure>
      <outcome_measure>HCV RNA change from baseline</outcome_measure>
      <outcome_measure>The proportion of participants with virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02378935</url>
  </study>
  <study rank="96">
    <nct_id>NCT02073656</nct_id>
    <title>Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
      <condition>HIV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>335</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-0115</other_id>
    </other_ids>
    <first_received>February 25, 2014</first_received>
    <start_date>February 2014</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>December 8, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with HCV RNA &lt; LLOQ on treatment</outcome_measure>
      <outcome_measure>For retreatment group only: Proportion of participants with HCV RNA &lt; LLOQ on treatment</outcome_measure>
      <outcome_measure>Change in HCV RNA from baseline</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
      <outcome_measure>For retreatment group only: Proportion of participants with sustained virologic response at 4, 12 and 24 weeks after discontinuation of therapy (SVR4, SVR12, and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants that maintain HIV-1 RNA &lt; 50 copies/mL while on treatment</outcome_measure>
      <outcome_measure>Change from baseline of serum creatinine at end of treatment, posttreatment weeks 12 and 24</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02073656</url>
  </study>
  <study rank="97">
    <nct_id>NCT02202980</nct_id>
    <title>Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">GS-9857</intervention>
      <intervention type="Drug">SOF/GS-5816</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>273</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-1468</other_id>
    </other_ids>
    <first_received>July 25, 2014</first_received>
    <start_date>August 2014</start_date>
    <completion_date>July 2016</completion_date>
    <last_updated>November 17, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of any adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with on treatment virologic failure and relapse</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response (ie, HCV RNA &lt; LLOQ) while on treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>New Zealand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02202980</url>
  </study>
  <study rank="98">
    <nct_id>NCT02102451</nct_id>
    <title>Control and Elimination Within Australia of Hepatitis C From People Living With HIV</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV</condition>
      <condition>HIV-HCV Coinfection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kirby Institute</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VHCRP1208</other_id>
    </other_ids>
    <first_received>March 20, 2014</first_received>
    <start_date>July 2014</start_date>
    <completion_date>December 2018</completion_date>
    <last_updated>April 28, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>CEASE</acronym>
    <primary_completion_date>December 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HCV viraemia</outcome_measure>
      <outcome_measure>Needs, behaviour and attitudes towards HCV treatment</outcome_measure>
      <outcome_measure>HCV treatment uptake</outcome_measure>
      <outcome_measure>Factors associated with HCV treatment and retreatment</outcome_measure>
      <outcome_measure>HCV treatment response rates</outcome_measure>
      <outcome_measure>Rates of HCV retreatment</outcome_measure>
      <outcome_measure>HCV transmission history</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02102451</url>
  </study>
  <study rank="99">
    <nct_id>NCT02613403</nct_id>
    <title>Efficacy and Safety of MK-3682B (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis</condition>
      <condition>Hepatitis C</condition>
      <condition>Digestive System Diseases</condition>
      <condition>Flaviviridae Infections</condition>
      <condition>Hepatitis, Viral, Human</condition>
      <condition>Liver Diseases</condition>
      <condition>RNA Virus Infections</condition>
      <condition>Virus Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MK- 3682B</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>3682-021</other_id>
      <other_id>2015-001483-19</other_id>
    </other_ids>
    <first_received>November 20, 2015</first_received>
    <start_date>December 2015</start_date>
    <completion_date>January 2017</completion_date>
    <last_updated>November 20, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After The End of Study Therapy (SVR12)</outcome_measure>
      <outcome_measure>Number of participants who experienced at least one adverse event</outcome_measure>
      <outcome_measure>Number of participants who discontinued study drug due to an adverse event</outcome_measure>
      <outcome_measure>Number of participants who experienced at least one serious adverse event</outcome_measure>
      <outcome_measure>Number of participants who experienced at least one drug-related adverse event</outcome_measure>
      <outcome_measure>Number of participants who experienced at least one serious and drug-related adverse event</outcome_measure>
      <outcome_measure>Number of participants who experienced at least one laboratory adverse event of interest</outcome_measure>
      <outcome_measure>Number of participants who experienced AST/ALT &gt;5 x upper limit normal at Week 4 or later</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02613403</url>
  </study>
  <study rank="100">
    <nct_id>NCT02531269</nct_id>
    <title>Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
      <collaborator>Basel Institute of Clinical Epidemiology (BICE)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-319</other_id>
    </other_ids>
    <first_received>August 11, 2015</first_received>
    <start_date>March 2015</start_date>
    <completion_date>January 2016</completion_date>
    <last_updated>December 8, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR12</outcome_measure>
      <outcome_measure>SVR4</outcome_measure>
      <outcome_measure>SVR24</outcome_measure>
      <outcome_measure>On-treatment Virological response at week 4 assessed by measuring viral load</outcome_measure>
      <outcome_measure>Virological response at the end of treatment (EOT) assessed by measuring viral load</outcome_measure>
      <outcome_measure>The occurrence of virological failure (on-treatment and relapse) assessed by measuring viral load</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Switzerland</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02531269</url>
  </study>
</search_results>
